| Symbol
| NDRG2
| contributors: mct/npt/pgu - updated : 21-09-2015
|
| HGNC name
| NDRG family member 2
|
| HGNC id
| 14460
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --low
|
| |
by hypermethylation of the promoter in grade III meningioma | | tumoral
|
|
| --low
|
| |
in liver and pancreatic cancers | | tumoral
|
|
| --low
|
| |
in glioblastoma, lung and breast cancer, and clinically aggressive meningioma | | constitutional
|
|
| --over
|
| |
in Alzheimer disease | | tumoral
|
|
| --over
|
|
overexpression inhibits glioblastoma (GBM) cell proliferation, and decreased NDRG2 expression correlates with decreased GBM patient survival  | | tumoral
|
|
| --low
|
| |
dependent on promoter methylation, was seen in the majority of oral squamous-cell carcinoma cases and in several cases of precancerous leukoplakia with dysplasia | | tumoral
|
|
| --low
|
| |
in colorectal cancer compared to benign colorectal tissues, and hypermethylation of NDRG2 was significantly correlated with nodal metastasis and poor differentiation | |
Variant & Polymorphism
| 
| |
| Candidate gene
| biomarker to predict aggressive behavior in patients with meningioma |
|
aberrant hypermethylation of the NDRG2 gene could be a molecular marker for detection and treatment of human colorectal cancers |
|
|
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | head and neck | | |
| potential target for therapeutic intervention in oral squamous-cell carcinoma |
| | |
|
| Tbx2 in the embryonic mouse heart at early stages of development throughout the myocardium of the heart tube both represses proliferation and impairs secondary heart field (SHF) progenitor cell deployment into the outflow tract (OFT), implicating the upregulation of Ndrg2 and downregulation of Ndrg4 expression |